Development of cross-resistance to tamoxifen in raloxifene-treated breast carcinoma cells

Anticancer Research

Volumn 22, Issue 3, 2002, Pages 1379-1384

  Gao, Z Q ^a   Gao, Z P ^a   Fields, J Z ^a   Boman, Bruce M ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Breast cancer; Cross resistance; Raloxifene; SERM; Tamoxifen

Indexed keywords

ESTROGEN RECEPTOR; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

ARTICLE; BREAST CARCINOMA; CANCER HORMONE THERAPY; CANCER RESISTANCE; CARCINOMA CELL; CELL CULTURE; CELL GROWTH; CONCENTRATION RESPONSE; CONTROLLED STUDY; CROSS RESISTANCE; HUMAN; HUMAN CELL; IC 50; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CELL DIVISION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; INHIBITORY CONCENTRATION 50; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN; TUMOR CELLS, CULTURED;

EID: 0036322205     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Tamoxifen, raloxifene, and the prevention of breast cancer
2. The interrelationships between ovarian-independent growth, tumorigenicity, invasiveness and antioestrogen resistance in the malignant progression of human breast cancer
3. Human breast cancer in the athymic nude mouse: Cytostatic effects of long-term anti-estrogen therapy
4. Clinical significance of tamoxifen withdrawal response
5. Response after withdrawal of tamoxifen and progestrogens in advanced breast cancer
6. Antagonism of estrogen action with a new benzothiophene derived antiestrogen
7. Cancer of the breast: The past decade (first of two parts)
8. Evaluation of a tetrazolium-based semiautomated colorimetric assay: Assessment of chemosensitivity testing
9. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays
10. Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability
11. The STAR (Study of Tamoxifen and Raloxifene) trial in West Virginia
12. Estrogen receptor mutations in tamoxifen-resistant breast cancer
13. Tissue-specific expression of MDRI ribozyme abolishes the multidrug resistance of colon cancer cells
14. Co-transfection of MDRI and MRP antisense RNAs abolishes the drug resistance in multidrug-resistant human lung cancer cells
15. Acquired tamoxifen resistance: Correlation with reduced breast tumor levels of tamoxifen and isomerization of trans-4hydroxytamoxifen
16. Molecular basis of agonism and antagonism in the oestrogen receptor
17. Tamoxifen for early breast cancer: An overview of the randomised trials
18. Antagonism of estrogen action with a new benzothiophene derived antiestrogen
19. Comparative analyses of mechanistic differences among antiestrogens
20. Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer